Given that CGAS is constitutively active in most tumor cells and results in the production of cGAMP, which can be internalized by bystander cells through gap junctions13, transporter solute carrier family 19 member 1 (SLC19A1)14, or volume-regulated anion channels15,178, targeting the STING1 pathway has the potential to overcome the immunosuppressive tumor microenvironment. The gene discussed is STING1; the disease is neoplasm.